CClinicalTrials.gg
Not yet recruitingNCT06331897Updated Mar 26, 2024

Bronchial Asthma & Its Exacerbation

An observational study in Bronchial Asthma, sponsored by Assiut University. Not yet recruiting. Open to participants aged 2 Years to 18 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-03-26.

Sponsored by Assiut University · Observational

From the registry’s dates

  • Primary completion was expected by Jan 2026, 9 months ago, but the record still lists the study as not yet recruiting.
Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
50
Ages
2 Years to 18 Years
Sex
All
01

Study summary

Our goals is to assess :

1¬_ the role of spirometer in case of asthma exacerbation 2_hematological parameters (N/L ratio \& platelet indices \&CRP )in asthma exacerbation for diagnosing and classifying asthma severity and its exacerbation

Read the detailed description

Bronchial asthma is a chronic inflammatory disease characterized by bronchial hyper-reactivity, reversible airway obstruction, and excessive mucus production that arises from an inappropriate stimulation of the immune system, especially by environmental aeroallergens .Bronchial asthma exacerbations are episodes described by progressive increase in symptoms of cough, wheezing, shortness of breath, and/or chest tightness, with a progressive decrease in lung function . Few tests are being used for diagnosis of asthma, but at present, no established biomarker is available that may be used for diagnosis and prognosis of asthma . Platelet indices and C-reactive protein (CRP) are markers that reflect a systemic inflammatory response . Bronchial obstruction, variable over time and reversible after using bronchodilator is the hallmark of the respiratory function in bronchial asthma. There are patients with \"atypical\" functional tests or in whom routine tests (spirometry, peak-flowmetry) are not sufficient for asthma diagnosis (thus necessitating more complex functional tests). Pulmonary function evaluation confirms the diagnostic, establishes disease severity and contributes to disease monitoring. Quality criteria verification (e.g. acceptability of the measurements and reproducibility of the parameters) should precede any interpretation . Neutrophilic, eosinophilic, paucigranulocytic or mixed granulocytic types are four various endotypes of asthma [6] depending on cell counts of peripheral blood .

Neutrophilic inflammations have been studied to be associated with a poor asthma control . In addition to persistent asthma symptoms and atopy, they have been reported to be associated with the presence of eosinophilic inflammation in asthmatic patients . Accordingly, NLR increase in asthmatics was considered. However, data related to NLR in Asthmatic patients is inadequate . Though association between asthma and NLR, was discovered by earlier researches in adults, recent researches did not study NLR relation to neutrophilic asthma . So, we aimed to assess the relation of NLR and bronchial asthma severity and to determine NLR discriminative performance between controlled and uncontrolled asthma . Platelet indices, which include the mean platelet volume (MPV), platelet distribution width (PDW), plateletcrit (PCT), and platelet large cell correlated with white blood cells, PaO2, and symptoms duration, and negatively correlated with forced expiratory volume in the first second, symptoms duration, and hs-CRP (P\<0.001).

Higher autophagy of neutrophils has been described in many pulmonary disorders as well as neutrophil extracellular traps and exosomes that has been newly studied as deriving from neutrophil . So neutrophils role in pulmonary diseases have been established. Despite pulmonary diseases pathogeneses are being studied widely, there is still more and more to get clarification of the discrepancy and complexity, particularly the contribution of different immune mechanisms in the progress of pulmonary disorders .

02

Conditions studied

  • Bronchial Asthma

Browse trials for

03

In context

Asthma

3,921 studies on the registry are indexed under Asthma; 507 are open to participants now.

This study's planned enrollment of 50 is below the median of 150 across 970 observational studies indexed under Asthma.

Browse Asthma studies →

Lead sponsor

Assiut University is the lead sponsor of 4,901 studies on the registry; 2,098 are open to participants now.

Of its 13 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
2 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

children group aged (2-18 years old ) who have bronchial asthma and its exacerbation

Eligibility criteria

Inclusion Criteria:

  • Clinical diagnosis of Bronchial asthma Disease
  • must be able to applied to spirometer

Exclusion Criteria: patients have 1-other chest diseases 2- diabetes mellitus and hypertension 3- malignancies and hematological disorder 4- valvular lesions , coronaries disease and heart failure 5- autoimmune diseases .

05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
50 participants (estimated)
Target follow-up
2 Years
Patient registry
Yes
06

What researchers measure

Primary outcomes

  1. Assessment of Broncial asthma & its exacerbation : the utility of laboratory investigation , chest imaging , pulmonary function tests

    to assess : the role of spirometer in case of asthma exacerbation

    Time frame: baseline

07

Study locations

No study locations are listed for this record.

08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 26, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06331897
Lead sponsor
Assiut University
Responsible party
Mohamed Ragab Kamel Mohamed (Resident of Pediatrics department, Assiut University) — Principal investigator
First posted
Mar 26, 2024
Start date
Jan 1, 2025 (estimated)
Primary completion
Jan 1, 2026 (estimated)
Completion
Jun 1, 2026 (estimated)
Last update
Mar 26, 2024

Study contacts

Mohamed ragab kamel, resident pediatrician
Contact
ibnragab34@gmail.com
+20 109 610 6605
emad hammad el daly, Professor of Pediatrics
Contact
emadhammad@aun.edu.eg

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Mar 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion